Zymeworks (ZYME) Cash from Investing Activities (2021 - 2026)
Zymeworks recorded quarterly Cash from Investing Activities of $70.0 million in Q1 2026, up 1203.26% quarter-over-quarter from $5.4 million in Q4 2025, and up 474.28% year-over-year from $12.2 million in Q1 2025.
Zymeworks' Cash from Investing Activities history runs 6 years deep, the most recent figure standing at $70.0 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities rose 474.28% year-over-year to $70.0 million; the TTM figure through Mar 2026 stood at $84.4 million (up 44.95% YoY), while the FY2025 annual figure was $26.7 million, down 31.2% from the prior year.
- Cash from Investing Activities came in at $70.0 million for Q1 2026 at Zymeworks, up from $5.4 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $72.3 million in Q3 2024 to a low of -$138.2 million in Q1 2023.
- A 5-year average of -$7.4 million and a median of -$6.2 million in 2024 frame the typical range for Cash from Investing Activities.
- Across the five-year window, Cash from Investing Activities slumped 1088.21% in 2022 and jumped 1129.3% in 2024, its largest moves.
- Zymeworks' Cash from Investing Activities stood at -$22.1 million in 2022, then jumped by 93.94% to -$1.3 million in 2023, then sank by 364.77% to -$6.2 million in 2024, then soared by 186.39% to $5.4 million in 2025, then surged by 1203.26% to $70.0 million in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered $70.0 million, $5.4 million, and $368000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.89 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 638.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -431.90 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -428.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -25.54 Mn |
| 10 | Zymeworks | 1.84 Bn | 1.47 Bn | - | 69.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 69.96 Mn |
| Mar 31, 2026 | 69.96 Mn |
| Dec 31, 2025 | 5.37 Mn |
| Dec 31, 2025 | 5.37 Mn |
| Sep 30, 2025 | 368,000.00 |
| Sep 30, 2025 | 368,000.00 |
| Jun 30, 2025 | 8.75 Mn |
| Jun 30, 2025 | 8.75 Mn |
| Mar 31, 2025 | 12.18 Mn |
| Mar 31, 2025 | 12.18 Mn |
| Dec 31, 2024 | -6.21 Mn |
| Dec 31, 2024 | -6.21 Mn |
| Sep 30, 2024 | 72.26 Mn |
| Sep 30, 2024 | 72.26 Mn |
| Jun 30, 2024 | -19.97 Mn |
| Jun 30, 2024 | -19.97 Mn |
| Mar 31, 2024 | -7.32 Mn |
| Mar 31, 2024 | -7.32 Mn |
| Dec 31, 2023 | -1.34 Mn |
| Dec 31, 2023 | -1.34 Mn |
| Sep 30, 2023 | -7.02 Mn |
| Sep 30, 2023 | -7.02 Mn |
| Jun 30, 2023 | -60.67 Mn |
| Jun 30, 2023 | -60.67 Mn |
| Mar 31, 2023 | -138.22 Mn |
| Mar 31, 2023 | -138.22 Mn |
| Dec 31, 2022 | -22.07 Mn |
| Dec 31, 2022 | -22.07 Mn |
| Sep 30, 2022 | -30.43 Mn |
| Sep 30, 2022 | -30.43 Mn |
| Jun 30, 2022 | -21.93 Mn |
| Jun 30, 2022 | -21.93 Mn |
| Mar 31, 2022 | 20.57 Mn |
| Mar 31, 2022 | 20.57 Mn |
| Dec 31, 2021 | -1.86 Mn |
| Dec 31, 2021 | -1.86 Mn |